Eprosartan: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
Undid revision 1158330492 by Qwv (talk) not primary name
 
(3 intermediate revisions by 2 users not shown)
Line 12: Line 12:
| pregnancy_AU = D
| pregnancy_AU = D
| pregnancy_AU_comment =
| pregnancy_AU_comment =
| pregnancy_US = D
| pregnancy_US_comment =
| pregnancy_category=
| pregnancy_category=
| dependency_liability =
| addiction_liability =
| routes_of_administration = [[Oral administration|By mouth]]
| routes_of_administration = [[Oral administration|By mouth]]
| ATC_prefix = C09
| ATC_prefix = C09
Line 79: Line 75:
}}
}}


'''Eprosartan''', sold under the brand name '''Teveten''' among others, is an [[angiotensin II receptor antagonist]] used for the treatment of [[hypertension|high blood pressure]].<ref>{{cite web | title=Eprosartan mesylate- eprosartan mesylate tablet, film coated | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=475394 | access-date=7 June 2023}}</ref>
⚫
'''Eprosartan''' is an [[angiotensin II receptor antagonist]] used for the treatment of [[hypertension|high blood pressure]]. It is marketed in the [[United States]] as ''Teveten'' by [[Abbvie]], the [[Corporate spin-off|spin-off]] of the pharmaceutical discovery division of [[Abbott Laboratories]]; it is marketed as ''Eprozar'' by [[Intas Pharmaceuticals]] in [[India]], and by [[Abbott Laboratories]] elsewhere. The compound came into the [[Abbott Laboratories]] cardiovascular pipeline with its acquisition of [[Kos Pharmaceuticals]] in 2006, which had licensed it, along with "a range of hypertensive treatments", from the [[Biovail Corporation]].<ref>Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [http://www.datamonitor.com/store/News/abbott_laboratories_kos_pharmaceuticals_a_wise_buy?productid=0BE8B1AB-14F9-4B92-99D2-80E8DC7ECA16], accessed 29 January 2015.</ref>


Eprosartan is sometimes paired with [[hydrochlorothiazide]], whereupon it is marketed in the US as ''Teveten HCT'' and elsewhere as ''Teveten Plus''.
Eprosartan is sometimes paired with [[hydrochlorothiazide]].<ref>{{cite web | title=Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet | website=DailyMed | date=3 January 2012 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1dfcac3-ef66-4d3e-9d58-37d3f516eb31 | access-date=7 June 2023}}</ref>


⚫
As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than [[enalapril]] (an [[ACE inhibitor]]), especially among the elderly.<ref>{{cite journal |vauthors=Ruilope L, Jäger B, Prichard B |title=Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial |journal=Blood Press. |volume=10 |issue=4 |pages=223–9 |year=2001 |pmid=11800061 |doi=10.1080/08037050152669747|s2cid=13063704 |doi-access=free }}</ref>
The drug acts on the [[renin–angiotensin system]] to decrease [[total peripheral resistance]] in two ways. First, it blocks the binding of [[angiotensin II]] to AT<sub>1</sub> receptors in vascular [[smooth muscle]], causing vascular dilatation. Second, it inhibits [[sympathetic nervous system|sympathetic]] [[norepinephrine]] production, further reducing blood pressure.


⚫
== History ==
⚫
As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than [[enalapril]] (an [[ACE inhibitor]]), especially among the elderly.<ref>{{cite journal |vauthors=Ruilope L, Jäger B, Prichard B |title=Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial |journal=Blood Press. |volume=10 |issue=4 |pages=223–9 |year=2001 |pmid=11800061 |doi=10.1080/08037050152669747|s2cid=13063704 }}</ref>
⚫
The compound came into the [[Abbott Laboratories]] cardiovascular pipeline with its acquisition of [[Kos Pharmaceuticals]] in 2006, which had licensed it, along with "a range of hypertensive treatments", from the [[Biovail Corporation]].<ref>Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [http://www.datamonitor.com/store/News/abbott_laboratories_kos_pharmaceuticals_a_wise_buy?productid=0BE8B1AB-14F9-4B92-99D2-80E8DC7ECA16], accessed 29 January 2015.</ref>


⚫
== References ==
== Structure activity Relationship ==
{{reflist}}
One feature that compares in Eprosartan versus other molecules is that Eprosartan is dosed relatively high at 400 to 800 mg/day. Eprosartan has an alpha-beta unsaturated hydrocarbon group which makes the compound difficult to absorb and contributes to its instability, thus there is a need for higher doses. The lipophilic aspects of the molecule also contribute to its low bioavailibility.

⚫
== See also ==
* [[Discovery and development of angiotensin receptor blockers]]

⚫
==References==
<references/>

== External links ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/eprosartan | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Eprosartan }}
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/eprosartan%20mesylate | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Eprosartan mesylate }}


{{Angiotensin II receptor antagonists}}
{{Angiotensin II receptor antagonists}}
Line 107: Line 94:
[[Category:Imidazoles]]
[[Category:Imidazoles]]
[[Category:Thiophenes]]
[[Category:Thiophenes]]
[[Category:AbbVie brands]]
[[Category:Drugs developed by AbbVie]]
[[Category:Benzoic acids]]
[[Category:Benzoic acids]]

Latest revision as of 19:27, 20 December 2023

Eprosartan
Clinical data
Trade namesTeveten
AHFS/Drugs.comMonograph
MedlinePlusa601237
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability15% (Eprosartan mesylate)
Metabolismnot metabolized
Elimination half-life5 to 9 hours
ExcretionKidney 10%, bile duct 90%
Identifiers
  • 4-({2-Butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H24N2O4S
Molar mass424.52 g·mol−1
3D model (JSmol)
  • O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3
  • InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+ checkY
  • Key:OROAFUQRIXKEMV-LDADJPATSA-N checkY
  (verify)

Eprosartan, sold under the brand name Teveten among others, is an angiotensin II receptor antagonist used for the treatment of high blood pressure.[1]

Eprosartan is sometimes paired with hydrochlorothiazide.[2]

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.[3]

History[edit]

The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.[4]

References[edit]

  1. ^ "Eprosartan mesylate- eprosartan mesylate tablet, film coated". DailyMed. Retrieved 7 June 2023.
  2. ^ "Teveten HCT- eprosartan mesylate and hydrochlorothiazide tablet". DailyMed. 3 January 2012. Retrieved 7 June 2023.
  3. ^ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061. S2CID 13063704.
  4. ^ Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [1], accessed 29 January 2015.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Eprosartan&oldid=1190943533"